Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2009 2
2011 1
2012 3
2013 2
2015 2
2016 1
2017 3
2018 2
2019 2
2020 1
2021 1
2022 2
2023 2
2024 3
2025 6
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Author response to letter to the editor, "Comment on "Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study"".
Etani Y, Noguchi T, Yukishima T, Kobayakawa T, Kashii M, Okamura G, Goshima A, Hirao M, Miura T, Kurihara T, Fukuda Y, Sugimoto A, Okada S, Nakata K, Ebina K. Etani Y, et al. Among authors: fukuda y. Bone. 2026 Feb;203:117727. doi: 10.1016/j.bone.2025.117727. Epub 2025 Nov 17. Bone. 2026. PMID: 41238037 No abstract available.
Author response to letter to the editor, "PINP-guided osteoporosis treatment selection: methodological considerations for cut-off, endpoint, fracture confounding and teriparatide heterogeneity".
Etani Y, Noguchi T, Yukishima T, Kobayakawa T, Kashii M, Okamura G, Goshima A, Hirao M, Miura T, Kurihara T, Fukuda Y, Sugimoto A, Okada S, Nakata K, Ebina K. Etani Y, et al. Among authors: fukuda y. Bone. 2026 Feb;203:117725. doi: 10.1016/j.bone.2025.117725. Epub 2025 Nov 12. Bone. 2026. PMID: 41238036 No abstract available.
Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study.
Etani Y, Noguchi T, Yukishima T, Kobayakawa T, Kashii M, Okamura G, Goshima A, Hirao M, Miura T, Kurihara T, Fukuda Y, Sugimoto A, Okada S, Nakata K, Ebina K. Etani Y, et al. Among authors: fukuda y. Bone. 2025 Dec;201:117627. doi: 10.1016/j.bone.2025.117627. Epub 2025 Sep 3. Bone. 2025. PMID: 40912668 Free article.
Iguratimod suppresses sclerostin and receptor activator of NF-κB ligand production via the extracellular signal-regulated kinase/early growth response protein 1/tumor necrosis factor alpha pathway in osteocytes and ameliorates disuse osteoporosis in mice.
Miura T, Etani Y, Noguchi T, Hirao M, Takami K, Goshima A, Kurihara T, Fukuda Y, Ochiai N, Kanamoto T, Nakata K, Okada S, Ebina K. Miura T, et al. Among authors: fukuda y. Bone. 2024 Apr;181:117026. doi: 10.1016/j.bone.2024.117026. Epub 2024 Feb 5. Bone. 2024. PMID: 38325651
An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
Ebina K, Nagayama Y, Kashii M, Tsuboi H, Okamura G, Miyama A, Etani Y, Noguchi T, Hirao M, Miura T, Fukuda Y, Kurihara T, Nakata K, Okada S. Ebina K, et al. Among authors: fukuda y. Osteoporos Int. 2024 May;35(5):841-849. doi: 10.1007/s00198-024-07019-2. Epub 2024 Jan 31. Osteoporos Int. 2024. PMID: 38296866 Free PMC article.
36 results